No Data
No Data
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104
Wedbush analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $92 to $104.According to TipRanks data, the analyst has a succes
Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104
Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake with a Outperform rating and announces Price Target of $104.
Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences
DelveInsight's analysts estimate that the psoriasis market is poised to show significant growth, mainly attributed to increasing prevalence, recent drug approvals, and anticipated launch of novel the